Magnetic resonance imaging measurement of iron overload

Purpose of reviewTo highlight recent advances in magnetic resonance imaging estimation of somatic iron overload. This review will discuss the need and principles of magnetic resonance imaging-based iron measurements, the validation of liver and cardiac iron measurements, and the key institutional requirements for implementation. Recent findingsMagnetic resonance imaging assessment of liver and cardiac iron has achieved critical levels of availability, utility, and validity to serve as the primary endpoint of clinical trials. Calibration curves for the magnetic resonance imaging parameters R2 and R2* (or their reciprocals, T2 and T2*) have been developed for the liver and the heart. Interscanner variability for these techniques has proven to be on the order of 5–7%. SummaryMagnetic resonance imaging assessment of tissue iron is becoming increasingly important in the management of transfusional iron load because it is noninvasive, relatively widely available and offers a window into presymptomatic organ dysfunction. The techniques are highly reproducible within and across machines and have been chemically validated in the liver and the heart. These techniques will become the standard of care as industry begins to support the acquisition and postprocessing software.

[1]  T. S. St. Pierre,et al.  Bi-exponential proton transverse relaxation rate (R2) image analysis using RF field intensity-weighted spin density projection: potential for R2 measurement of iron-loaded liver. , 2003, Magnetic resonance imaging.

[2]  D. Pennell,et al.  Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. , 2006, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[3]  C. McLaren,et al.  Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major , 1993, American journal of hematology.

[4]  M. Kami,et al.  Hepatic iron concentration and total body iron stores in thalassemia major. , 2000, The New England journal of medicine.

[5]  C. McLaren,et al.  Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. , 1994, The New England journal of medicine.

[6]  M. Harada,et al.  Evaluation of bone marrow iron by magnetic resonance imaging , 1997, Annals of Hematology.

[7]  G. Mancosu,et al.  Does iron concentration in a liver needle biopsy accurately reflect hepatic iron burden in beta-thalassemia? , 2000, Clinical chemistry.

[8]  H. Bonkovsky,et al.  Usefulness and limitations of laboratory and hepatic imaging studies in iron-storage disease. , 1990, Gastroenterology.

[9]  G. Bydder,et al.  Computed tomography for determining liver iron content in primary haemochromatosis. , 1980 .

[10]  A. Castriota-Scanderbeg,et al.  Methods for evaluating iron stores and efficacy of chelation in transfusional hemosiderosis. , 1991, Haematologica.

[11]  D. Fitchett,et al.  Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. , 1980, Cardiovascular research.

[12]  D N Firmin,et al.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.

[13]  P. Storey,et al.  R2* imaging of transfusional iron burden at 3T and comparison with 1.5T , 2007, Journal of magnetic resonance imaging : JMRI.

[14]  R Dick,et al.  COMPUTED TOMOGRAPHY FOR DETERMINING LIVER IRON CONTENT IN PRIMARY HAEMOCHROMATOSIS , 1981, British medical journal.

[15]  G. Brittenham,et al.  Noninvasive measurement of iron: report of an NIDDK workshop. , 2003, Blood.

[16]  S. De Virgiliis,et al.  Serum ferritin, liver iron stores, and liver histology in children with thalassaemia. , 1980, Archives of disease in childhood.

[17]  K. Lindor,et al.  Outcome of Patients Hospitalized for Complications after Outpatient Liver Biopsy , 1993, Annals of Internal Medicine.

[18]  B. Bacon,et al.  Iron overload: causes and consequences. , 1987, Annual review of nutrition.

[19]  G. Lucarelli,et al.  Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies , 1995, British journal of haematology.

[20]  Thomas D. Coates,et al.  Cardiac Iron Determines Cardiac T2*, T2, and T1 in the Gerbil Model of Iron Cardiomyopathy , 2005, Circulation.

[21]  R. Fischer,et al.  Using SQUID biomagnetic liver susceptometry in the treatment of thalassemia and other iron loading diseases. , 2000, Transfusion science.

[22]  R. Ordidge,et al.  The measurement of R2, R2* and R2' in HIV-infected patients using the prime sequence as a measure of brain iron deposition. , 1997, Magnetic resonance imaging.

[23]  J A Frank,et al.  Hepatic hemosiderosis in non‐human primates: Quantification of liver iron using different field strengths , 1997, Magnetic resonance in medicine.

[24]  D. Pennell,et al.  Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance , 2004, British journal of haematology.

[25]  Mark A Westwood,et al.  Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia , 2003, Journal of magnetic resonance imaging : JMRI.

[26]  T. S. St. Pierre,et al.  Reduction of respiratory motion artifacts in transverse relaxation rate (R2) images of the liver. , 2004, Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society.

[27]  T. Coates,et al.  MRI detects myocardial iron in the human heart , 2006, Magnetic resonance in medicine.

[28]  Noninvasive quantitation of liver iron in dogs with hemochromatosis using dual-energy CT scanning. , 1982, Investigative radiology.

[29]  C. Cann,et al.  Noninvasive quantitation of liver iron in dogs with hemochromatosis using dual-energy CT scanning. , 1981, Investigative radiology.

[30]  D. Pennell,et al.  A single breath‐hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload , 2003, Journal of magnetic resonance imaging : JMRI.

[31]  G. Brittenham,et al.  Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.

[32]  J. Villeneuve,et al.  Variability in hepatic iron concentration measurement from needle-biopsy specimens. , 1996, Journal of hepatology.

[33]  G. McLaren,et al.  Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy. , 1983, Critical reviews in clinical laboratory sciences.

[34]  Huaqing Zhao,et al.  1/T2 and magnetic susceptibility measurements in a gerbil cardiac iron overload model. , 2005, Radiology.

[35]  B. Gersh,et al.  Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. , 1987, Journal of the American College of Cardiology.

[36]  Marvin D Nelson,et al.  Mechanisms of tissue–iron relaxivity: Nuclear magnetic resonance studies of human liver biopsy specimens , 2005, Magnetic resonance in medicine.

[37]  Ioannis Seimenis,et al.  R2 relaxometry with MRI for the quantification of tissue iron overload in β‐thalassemic patients , 2006, Journal of magnetic resonance imaging : JMRI.

[38]  T. Coates,et al.  MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. , 2005, Blood.

[39]  R. Engelhardt,et al.  Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility , 2003, The Lancet.

[40]  J. Howard,et al.  DIAGNOSTIC EFFICACY OF HEPATIC COMPUTED TOMOGRAPHY IN THE DETECTION OF BODY IRON OVERLOAD , 1983, Gastroenterology.

[41]  I. Papassotiriou,et al.  Deferiprone as an oral iron chelator in sickle cell disease , 2005, Annals of Hematology.

[42]  R. Moats,et al.  Physiology and Pathophysiology of Iron Cardiomyopathy in Thalassemia , 2005, Annals of the New York Academy of Sciences.

[43]  N. Olivieri,et al.  Progression of iron overload in sickle cell disease. , 2001, Seminars in hematology.

[44]  A. Hoffbrand,et al.  Hepatic iron concentration combined with long‐term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major , 2000, British journal of haematology.

[45]  Roger Williams,et al.  Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. , 2005, American journal of clinical pathology.

[46]  T. S. St. Pierre,et al.  Quantitative mapping of transverse relaxivity (1/T(2)) in hepatic iron overload: a single spin-echo imaging methodology. , 2000, Magnetic resonance imaging.

[47]  K. Ehlers,et al.  LONGITUDINAL STUDY OF CARDIAC FUNCTION IN THALASSEMIA MAJOR * , 1980, Annals of the New York Academy of Sciences.

[48]  A. Cnaan,et al.  Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. , 2004, Haematologica.

[49]  T. S. St. Pierre.  Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. , 2003, Lancet.

[50]  D. Pennell,et al.  Development of Thalassaemic Iron Overload Cardiomyopathy despite Low Liver Iron Levels and Meticulous Compliance to Desferrioxamine , 2006, Acta Haematologica.

[51]  C. McLaren,et al.  Hepatic iron concentration and total body iron stores in thalassemia major. , 2000, The New England journal of medicine.

[52]  M. Bronner,et al.  Quantitative study of the variability of hepatic iron concentrations. , 1999, Clinical chemistry.

[53]  T. Coates,et al.  Improved R2* measurements in myocardial iron overload , 2006, Journal of magnetic resonance imaging : JMRI.

[54]  Michel Bourel,et al.  Assessment of liver iron content in 271 patients: A reevaluation of direct and indirect methods , 1981 .

[55]  J. H. MacMillan,et al.  Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.

[56]  T G St Pierre,et al.  A magnetic resonance imaging based method for measurement of tissue iron concentration in liver arterially embolized with ferrimagnetic particles designed for magnetic hyperthermia treatment of tumors. , 2003, Magnetic resonance imaging.

[57]  D. Weatherall,et al.  Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility , 2003, The Lancet.

[58]  T. S. St. Pierre,et al.  Proton transverse relaxation rate (R2) images of iron‐loaded liver tissuepping local tissue iron concentrations with MRI , 2003 .

[59]  N. Gourtsoyiannis,et al.  Adrenal glands in beta-thalassemia major: magnetic resonance (MR) imaging features and correlation with iron stores , 2005, European Radiology.

[60]  M. Midiri,et al.  MR imaging technique for the diagnosis of pituitary iron overload in patients with transfusion-dependent beta-thalassemia major. , 1998, AJNR. American journal of neuroradiology.

[61]  M. Argyropoulou,et al.  T2 relaxation rate as an index of pituitary iron overload in patients with beta-thalassemia major. , 2000, AJR. American journal of roentgenology.

[62]  T. Meade,et al.  Mimicking liver iron overload using liposomal ferritin preparations , 2004, Magnetic resonance in medicine.

[63]  E. Eracleous,et al.  Low Serum Ferritin Levels are Misleading for Detecting Cardiac Iron Overload and Increase the Risk of Cardiomyopathy in Thalassemia Patients. The Importance of Cardiac Iron Overload Monitoring Using Magnetic Resonance Imaging T2 and T2* , 2006, Hemoglobin.

[64]  J. Tripp,et al.  Magnetic-susceptibility measurement of human iron stores. , 1982, The New England journal of medicine.

[65]  G. Ooi,et al.  Magnetic resonance screening of iron status in transfusion‐dependent β‐thalassaemia patients , 2004, British journal of haematology.

[66]  T. S. St. Pierre,et al.  The form of iron oxide deposits in thalassemic tissues varies between different groups of patients: a comparison between Thai beta-thalassemia/hemoglobin E patients and Australian beta-thalassemia patients. , 1998, Biochimica et biophysica acta.

[67]  P D Griffiths,et al.  Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. , 2000, Brain : a journal of neurology.

[68]  N. Khaper,et al.  Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy , 2006, Journal of Molecular Medicine.

[69]  Marvin D Nelson,et al.  Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. , 2004, Blood.

[70]  I. Papassotiriou,et al.  Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease , 2004, British journal of haematology.

[71]  P. van Eyken,et al.  Uneven hepatic iron and phosphorus distribution in beta-thalassemia. , 1995, Journal of hepatology.

[72]  V. Sébille,et al.  Non-invasive assessment of hepatic iron stores by MRI , 2004, The Lancet.

[73]  T. S. St. Pierre,et al.  Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. , 2005, Blood.

[74]  Sheryl E. Koch,et al.  L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy , 2003, Nature Medicine.

[75]  Mark A Westwood,et al.  Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. , 2006, Haematologica.

[76]  J. H. MacMillan,et al.  Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .